BIO three-lens brief
Evidence-based stock research on BIO. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 94% of its 52-week range — near the top of the band.
- Trading at 94% of its 52-week range — near the top of the band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- P/E of 10.3 — trading at a value multiple.
- Reported earnings on 2026-11-04.
BIO closed at $386.00 (-0.12%) as of 2026-11-12. Market cap: $10.38B. P/E (trailing) 10.3. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; p/E of 10.3 — trading at a value multiple.. Concerns: trading at 94% of its 52-week range — near the top of the band.. Last quarter: Revenue $656.40M, free cash flow $271.65M.
Why three lenses on BIO, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BIO across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BIO" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BIO brief"></iframe>